You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

 

CPD

The Shifting Epidemiology of Dengue: From Climate Change to Urbanization

  • Authors: Anna Stewart-Ibarra, PhD, MPA
  • CPD Released: 4/20/2022
  • Valid for credit through: 4/20/2023
Start Activity

  • Credits Available

    Non-US Physicians - maximum of 0.25 CPD

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US primary care physicians, infectious disease specialists, and pediatricians.

The goal of this activity is for learners to be better informed about the increased threat of dengue infection beyond traditional areas of endemicity.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Shifting epidemiology of dengue
    • Factors responsible for expansion/adaptation of dengue-carrying vector(s)


Disclosures

WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.

Disclosures for additional planners can be found here.


Faculty

  • Anna Stewart-Ibarra, PhD, MPA

    Science Director/Directora de Cienci
    Inter-American Institute for Global Change Research/Instituto Interamericano para la Investigación del Cambio Global
    Montevideo, Uruguay

    Disclosures

    No relevant financial relationships

Editors

  • Gillian Griffith, BA (Mod), MA

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Disclosure: Gillian Griffith, BA (Mod), MA, has no relevant financial relationships.

  • Jenny Engelmoer, PhD

    Medical Writer, WebMD Global, LLC

    Disclosures

    Disclosure: Jenny Engelmoer, PhD, has no relevant financial relationships.

Compliance Reviewer

  • Susan L. Smith, MN, PhD

    Associate Director, Accreditation and Compliance

    Disclosures

    Disclosure: Susan L. Smith, MN, PhD, has no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.25 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

The Shifting Epidemiology of Dengue: From Climate Change to Urbanization

Authors: Anna Stewart-Ibarra, PhD, MPAFaculty and Disclosures

CPD Released: 4/20/2022

Valid for credit through: 4/20/2023

processing....

THE GROWING THREAT OF DENGUE: SHIFTING EPIDEMIOLOGY

Current Endemic Landscape of Dengue

The threat of dengue has expanded beyond traditional areas of endemicity, with over half the world's population now estimated to live in areas at risk of dengue virus transmission.[1] Multiple factors have contributed to the recent spread of dengue, including globalization, climate change, and increasing urbanization.[2,3] Identified in 2019 by the World Health Organization as one of the top 10 threats to global health,[4] dengue remains a significant international public health problem, causing 24 million to 130 million symptomatic cases and 10,000 to 50,000 deaths annually.[1, 5,6] As with many other neglected tropical diseases, dengue has significant economic and social effects, focused mainly in low- and middle-income countries endemic for the disease, with associated costs estimated at $9 billion US annually.[7] Decision-makers around the world need to adequately plan and respond to the increasing global threat of dengue.[3]

Dengue Transmission

Dengue virus is a flavivirus transmitted primarily by Aedes aegypti and less commonly by Aedes albopictus mosquito vectors.[8] The virus is maintained in endemic/epidemic cycles primarily in subtropical and tropical urban areas, with Ae. aegypti populations living and breeding in close contact with humans.[2] Transmission of the virus primarily occurs through bites to humans by infected mosquitoes and subsequent infection of mosquitoes from biting viremic humans (horizontal transmission) (Figure 1), although some vertical transmission (directly from adults to offspring) and venereal transmissions (from infected males to uninfected females) occur within mosquito populations.[9] Female mosquitoes become infected with dengue virus if they ingest blood from an infected human during the acute febrile and viremic phase of the illness.[2] Initially, the virus infects the midgut cells, followed by other tissues and ultimately the salivary glands approximately 8 to 10 days after infection. At this point, the mosquito can pass the virus to a human during feeding, with symptomatic disease occurring approximately 4 to 7 days later. Mosquitoes remain infected and can therefore infect multiple humans during their life span (approximately 1 to 2 weeks).[2]

Figure 1. Transmission Cycle of Dengue in Humans and Mosquitoes[2]

 

There are 4 dengue virus serotypes (DENV-1, -2, -3, and -4), which co-circulate in many endemic areas and, while infection with 1 serotype is thought to provide lifelong protection against that serotype, together with transient cross-protection against other serotypes, an individual can have more than 1 infection during their lifetime. Subsequent infection with a different serotype leads to increased risk of hospitalization and more severe disease, at least in part due to antibody-dependent enhancement.[10-12] Additionally, as mosquito vectors can be infected with multiple arboviruses within endemic regions, there is the potential for co-infection with other potentially serious infections, including Zika and chikungunya.[13,14]

  • Print